Karyopharm Therapeutics (KPTI) Earnings Date, Estimates & Call Transcripts $0.52 -0.03 (-5.24%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.53 +0.01 (+2.42%) As of 10/23/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings Karyopharm Therapeutics Earnings Summary Karyopharm Therapeutics released Q2 2026 earnings on August 13, 2026, reporting an EPS of -$2.32, which missed analysts' consensus estimates of -$1.37 by $0.95. Quarterly revenue was reported to be $33.43 million, above analyst estimates of $32.19 million. With a trailing EPS of -$13.09, Karyopharm Therapeutics' earnings are expected to grow next year, from ($4.70) to ($2.33) per share. Upcoming Q3 Earnings DateNov. 2Before Market OpensEstimatedConsensus EPS (Aug. 13) -$1.37 Actual EPS (Aug. 13) -$2.32 Missed By -$0.95 Actual Revenue (Aug. 13) $33.43MQ2 2026 Earnings ResourcesQ2 2026 Earnings ReportConference Call Transcript & Audio Slide Deck Press Release (8-K) Quarterly Report (10-Q)KPTI Upcoming EarningsKaryopharm Therapeutics' Q3 2026 earnings is estimated for Monday, November 2, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportSlide DeckFull Screen Slide DeckPowered by Get Karyopharm Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Karyopharm Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataKPTI Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KPTI Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Karyopharm Therapeutics Upcoming Earnings ConsensusReport DateNovember 2, 2026Consensus EPS Estimate-$1.16Consensus Revenue Estimate$33.54MKaryopharm Therapeutics Analyst EPS Estimates & Company GuidanceLow, high and average are individual analyst estimates we track. Guidance columns are the company's own outlook, and the revenue estimate was recorded when that guidance was issued.QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Revenue GuidanceRevenue Estimate at GuidanceQ1 20261-$1.05-$1.05-$1.05Q2 20261-$1.38-$1.38-$1.38Q3 20261-$1.05-$1.05-$1.05Q4 20261-$0.85-$0.85-$0.85FY 20264-$4.33-$4.33-$4.33 Karyopharm Therapeutics Earnings History by Quarter 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 3M6MYTD1Y2Y3Y5Y10Y More filters Fewer filters Done 0 Results Export DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/2/2026(Estimated)--$1.16---$33.54M-8/13/2026Q2 2026-$1.37-$2.32 -$0.95-$2.32$32.19M$33.43M5/14/2026Q1 2026-$1.45-$1.24+$0.21-$1.24$31.40M$35.07M2/13/2026Q4 2025-$2.26-$2.23+$0.03-$5.71$33.16M$34.08M11/3/2025Q3 2025-$3.30-$3.82 -$0.52-$3.82$39.56M$44.04M8/11/2025Q2 2025-$3.80-$4.32 -$0.52-$4.32$37.92M$37.93M5/12/2025Q1 2025-$4.21-$2.77+$1.44-$2.77$35.12M$30.02M2/19/2025Q4 2024-$3.90-$3.60+$0.30-$0.24$30.29M$30.54M11/5/2024Q3 2024-$4.05-$3.90+$0.15-$0.26$37.86M$38.78M Karyopharm Therapeutics Earnings - Frequently Asked Questions When is Karyopharm Therapeutics' earnings date? Karyopharm Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 2nd, 2026 based off last year's report dates. Learn more on KPTI's earnings history. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics updated its FY 2026 earnings guidance on Thursday, August, 13th. The company issued revenue guidance of $130.0 million-$150.0 million, compared to the consensus revenue estimate of $133.5 million. Did Karyopharm Therapeutics beat their earnings estimates last quarter? In the previous quarter, Karyopharm Therapeutics (NASDAQ:KPTI) missed the analysts' consensus estimate of ($1.37) by $0.95 with a reported earnings per share (EPS) of ($2.32). Learn more on analysts' earnings estimate vs. KPTI's actual earnings. How can I listen to Karyopharm Therapeutics' earnings conference call? The conference call for Karyopharm Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Karyopharm Therapeutics' conference call transcript? The conference call transcript for Karyopharm Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Karyopharm Therapeutics generate each year? Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded annual revenue of $146.07 million. How much profit does Karyopharm Therapeutics generate each year? Karyopharm Therapeutics (NASDAQ:KPTI) has a recorded net income of -$196.04 million. KPTI has generated -$13.09 earnings per share over the last four quarters. What is Karyopharm Therapeutics' EPS forecast for next year? Karyopharm Therapeutics' earnings are expected to grow from ($4.70) per share to ($2.33) per share in the next year. More Earnings Resources from MarketBeat Related Companies MIRA Earnings Date TAOX Earnings Date ABVC Earnings Date PLRZ Earnings Date AYTU Earnings Date TXMD Earnings Date SCLX Earnings Date QNTM Earnings Date QNRX Earnings Date UPC Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-OffPalantir's Next Big Test Isn't a Partnership—It's the Numbers Earnings data for NASDAQ:KPTI is sourced from Fiscal.ai, with the most recent quarter reported on 8/13/2026. New results are added as companies report their earnings. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
